RENB Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 21.72%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $480,575.22

Renovaro Insider Trading History Chart

Renovaro Share Price & Price History

^$0.38

▲ +0.0144 (3.97%)

As of 04/11/2025 05:00 PM ET

Days: 30 | 90 | 365

Renovaro Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/29/2024	Anderson Wittekind William	Major Shareholder	Sell	1,114	$1.30	$1,448.20	840,319
7/17/2024	Anderson Wittekind William	Major Shareholder	Sell	16,362	$1.46	$23,888.52	841,433
7/15/2024	Anderson Wittekind William	Major Shareholder	Sell	21,954	$1.41	$30,955.14	875,795
7/11/2024	Anderson Wittekind William	Major Shareholder	Sell	14,896	$1.51	$22,492.96	897,749
7/9/2024	Anderson Wittekind William	Major Shareholder	Sell	4,630	$1.53	$7,083.90	969,645
7/5/2024	Anderson Wittekind William	Major Shareholder	Sell	60,000	$1.55	$93,000.00	974,275
7/3/2024	Anderson Wittekind William	Major Shareholder	Sell	50,000	$1.51	$75,500.00	1,034,275
7/1/2024	Anderson Wittekind William	Major Shareholder	Sell	60,000	$1.56	$93,600.00	1,118,828
6/27/2024	Anderson Wittekind William	Major Shareholder	Sell	14,671	$1.50	$22,006.50	1,178,828
6/25/2024	Anderson Wittekind William	Major Shareholder	Sell	20,000	$1.58	$31,600.00	1,243,499
6/14/2024	Anderson Wittekind William	Major Shareholder	Sell	50,000	$1.58	$79,000.00	1,263,499

See Full Table

SEC Filings (Institutional Ownership Changes) for Renovaro (NASDAQ:RENB)

71.41% of Renovaro stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Renovaro Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/17/2025	ProShare Advisors LLC	32,570	$27K	0.0%	N/A	0.021%
2/17/2025	Nuveen Asset Management LLC	151,681	$0.13M	0.0%	+128.8%	0.096%
2/17/2025	MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	64,923	$54K	0.0%	+174.8%	0.041%
2/17/2025	Deutsche Bank AG	127,437	$0.11M	0.0%	N/A	0.080%
2/17/2025	Cantor Fitzgerald L. P.	300,000	$0.25M	0.0%	+200.0%	0.189%
2/14/2025	Northern Trust Corp	889,357	$0.74M	0.0%	+49.5%	0.560%
2/14/2025	The Manufacturers Life Insurance Company	45,797	$38K	0.0%	N/A	0.029%
2/14/2025	Voya Investment Management LLC	35,312	$30K	0.0%	N/A	0.022%
2/14/2025	Price T Rowe Associates Inc. MD	45,198	$38K	0.0%	+183.5%	0.028%
2/14/2025	MetLife Investment Management LLC	75,454	$63K	0.0%	N/A	0.048%
2/13/2025	Barclays PLC	179,844	$0.15M	0.0%	+158.7%	0.113%
2/13/2025	Wells Fargo & Company MN	59,101	$49K	0.0%	+224.9%	0.037%
2/12/2025	Geode Capital Management LLC	2,332,634	$1.95M	0.0%	+48.4%	1.470%
2/12/2025	JPMorgan Chase & Co.	353,833	$0.30M	0.0%	+280.4%	0.223%
2/11/2025	Corebridge Financial Inc.	57,495	$48K	0.0%	+114.8%	0.036%
2/6/2025	Charles Schwab Investment Management Inc.	362,126	$0.30M	0.0%	+82.0%	0.228%
2/4/2025	Bank of New York Mellon Corp	223,915	$0.19M	0.0%	+137.2%	0.141%
1/31/2025	New York State Common Retirement Fund	52,500	$44K	0.0%	-21.3%	0.033%
1/30/2025	Rhumbline Advisers	112,960	$94K	0.0%	+122.6%	0.071%
1/17/2025	SG Americas Securities LLC	51,725	$43K	0.0%	+193.3%	0.033%
12/26/2024	JPMorgan Chase & Co.	93,010	$45K	0.0%	+347.6%	0.059%
11/19/2024	Barclays PLC	69,531	$34K	0.0%	+315.7%	0.044%
11/16/2024	Geode Capital Management LLC	1,572,290	$0.76M	0.0%	-9.0%	0.972%
11/15/2024	Barclays PLC	69,531	$34K	0.0%	+315.7%	0.043%
11/15/2024	State Street Corp	1,323,832	$0.64M	0.0%	+3.8%	0.819%
8/1/2024	Rhumbline Advisers	45,197	$79K	0.0%	N/A	0.031%
7/26/2024	Bank of New York Mellon Corp	125,461	$0.22M	0.0%	N/A	0.085%
5/17/2024	Tidal Investments LLC	36,972	$98K	0.0%	N/A	0.026%
5/10/2024	Vanguard Group Inc.	3,916,672	$10.38M	0.0%	+904.0%	2.726%
5/7/2024	SG Americas Securities LLC	17,263	$46K	0.0%	N/A	0.012%

Data available starting January 2016

See Full Table

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

Today's Range

Now: $0.38

$0.36

$0.39

50 Day Range

MA: $0.71

$0.36

$1.19

52 Week Range

Now: $0.38

$0.32

$2.70

Volume

997,274 shs

Average Volume

920,627 shs

Market Capitalization

$59.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.59

Who are the company insiders with the largest holdings of Renovaro?: Renovaro's top insider investors include:
Anderson Wittekind William (Major Shareholder)
Learn More about top insider investors at Renovaro.